Strategic partnerships Leverage Nonacus ongoing collaborations with healthcare providers like The London Clinic and NHS-linked services to position GALEAS Bladder and GALEAS Tumor as non-invasive, cost-saving diagnostic options for urology and oncology channels.

Clinical adoption Target hospitals and labs expanding precision oncology workflows; emphasize GALEAS panels' non-invasive testing and rapid genomics profiling to reduce invasive procedures and improve patient throughput.

NHS integration Highlight opportunities within NHS pathways for expanding non-invasive cancer detection; align GALEAS testing services with national screening and diagnostic protocols to accelerate adoption and reimbursement prospects.

At-home testing appeal Promote at-home and urine-based tests like GALEAS Bladder as patient-friendly screening options to drive demand in gastro-uro-oncology clinics, primary care networks, and ambulatory care settings.

Expand genomic offerings Cross-sell GALEAS Hereditary Plus and Tumor panels to laboratories and clinics already using NGS testing; emphasize streamlined workflows, comprehensive panels, and alignment with international guidelines to win additional volume.